Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-05
1999-06-22
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 23, 514 54, 514777, A61K 3813, A61K 4726, A61K 31715
Patent
active
059143142
ABSTRACT:
A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
REFERENCES:
patent: 2583096 (1952-01-01), Hididian et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4272522 (1981-06-01), Balazs
patent: 4303676 (1981-12-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leschiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4943560 (1990-07-01), Wigness et al.
patent: 4946870 (1990-08-01), Partain, III et al.
patent: 4956381 (1990-09-01), Bollinger et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 4996193 (1991-02-01), Hewitt et sl.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5166331 (1992-11-01), della Valle et al.
patent: 5411952 (1995-05-01), Kaswan
Van Nostrand's Scientific Encyclopedia, 4.sup.th ed. 1968. p. 214.
Blakeslee, S., "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of The Glove and Mail, Toronto, Ont., p. D4.
Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine, vol. 8, No. 16, Aug. 21, 1989, p. 1.
The Merck Index, Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751-752 (1989).
Braun, DP et al., "Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists", Immunity to Cancer II, 1989, pp. 439-448, Alan R. Liss, Inc.
Goodwin, J.S., Prostaglandin E and Cancer Growth: Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentin Agents in Cancer Therapy, Raven Press, New York (1981), pp. 393-415.
Asculai, Dr. S., "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", Antimicobial Agents and Chemotherapy, Apr. 1978, pp. 686-690.
Sneader, W.E., Chemical Abstracts, vol. 76, No. 10, Possible Mechanism for Action of DMSO on Percutaneous absorption, J. Pharm. Pharmcol, 1971, 23 (Supp).
International Preliminary Examination Report for PCT/CA90/00306 and attachement substitute claims (1991).
Alaverdyan et al, "Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia", Bulletin of Experimental Biology & Medicine 1967: 64(9): 967-969.
Balazs et al, "The rheoiogical properties and biological function of hyaluronic acid", Chem. and Mol. Biol. of the Intercellular Matrix, vol. 3, 1970, pp. 1241-1253.
Balezs E.A. et al, "Hyaluronic acid: Its structure and use", Cosmetics & Toiletries, Polymers in Cosmetics 1984:99: 65-72.
Camber O. et al, "Diffusion of some low molecular weight compounds in sodium hyaluronate", Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Camber O. et al, "Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits", Current Eve Research 1987: 6(6): 779-784.
Chang S-C, "Prodrug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit", Dissertation Abstracts International 1988; 49(2): 367-B.
Cravioto R O et al, Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid from Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); vol. 111:520-521.
Gieldanowski J et al, "Studies on immunosuppresive and anti-inflammatory effects of adriamycin", Arch. Immunol. Ther. Exp. (1980); 28(3): 439-446.
Hassan, H.G., et al., "Effects of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29: 384-388.
Hurd, E.R., "Immunosuppresive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate", Arthritis and Rheumatism (1973 Jan./Feb.); 16(1): 84-88.
Idson B, "Polymers in skin cosmetics", Cosmetics & Toiletries 1988; 103:63-68.
Johansson A. et al, "Effect of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29:736-738.
Kalbhen D.A., "The inhibitory effects of steroid and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon.RTM.)", Z. Rheumatol (1982): 41: 202-211.
Katsu M. et al., "Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence", Nippon Rinsho (Jan. 1986) 26(1): 89-95.
Kreis M. et al., "Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients" Transplantation (Feb. 1984); 37(2): 139-145.
McIlwraith W, "Current concepts in equine degenerative joint disease", Journal of the Am. Veterinary Medical Assoc. Feb. 1, 1982; vol. 180: 239-250.
Mizushima Y., "Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future", Nippon Rinsho (Jan. 1986); 26(1): 61-65.
Nizolek D.J.H. et al, "Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A Review" The Cornell Veterinarian 1981: 71(4): 355-375.
Pigman W et al, "Amide hyaluronique et facteurs de permeabilite tissulaire" Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202.
Pruett RC, et al, "Hyaluronic acid Vitreious substitute", In: Vitreous Surgery and Advances in Fundus Diagnosis and Treatment, H. McKenzie Freeman et al Editors, Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444.
Reim M et al, "Surgical procedures in the treatment of most severe eye burns" Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.
Rydell N et al, "Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on grandulation tissue formation" Clinical Orthopaedics and Related Research 1971; (Oct. 1980): 25-29.
Saba P et al, "Investigation of antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex", Current Therapeutic Research 1978; 23(4): 455-463.
Stegmann R et al, "Use of sodium hyaluronate in sever penetrating ocular trauma" Acta Ophthalmol. 1986; 18: 9-13.
Trabucci E et al, "Prevention of wound dehiscense in severely obese patients with jejuno-ileal by-pass: the role of hyaluronic acid" Pharmatherapeutica 1988; 5(4): 233-239.
Sertoli P et al., L'acido jaluronico, per uso topico, nella cura della ulcere trofocircolatorie degli arti inferiori (Comunicazioni) Giornale Italiano di Dermatologia 1970; 45(8): 468-471.
Walther M, "The Prevention of Strine Cutis Distansae During Pregnancy", Minerva Ginecologica (1981) Vo. 33: 497-499.
Weirich E G et al, "Dermatopharmacology of salicyclic acid. III. Topical contra-inflammatory effects of salicyclic acid and other drugs in animal experiments", Dermatologica (1976); 152(2): 87-88.
U.S. Patent Application 07/338,106, filed Apr. 1989, Falk.
Asculai Samuel S.
Falk Rudolf Edgar
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Russel Jeffrey E.
Sarkis Marcelo K.
LandOfFree
Use of a form of hyaluronic acid and a medicinal agent for reduc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a form of hyaluronic acid and a medicinal agent for reduc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a form of hyaluronic acid and a medicinal agent for reduc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1708157